EnPlusOne is on a mission to bring RNA and RNA solutions to the world. Its ezRNA™ synthesis platform is a stepwise innovation that can incorporate a diverse array of nucleotide modifications and promises a manufacturing process that can sustainably deliver therapeutic RNA at commercial scales. In addition to direct RNA synthesis, EnPlusOne's ezRNA™ platform supports a vast array of RNA solution applications. For more information, please visit www.enplusonebio.com
| Website | http://www.enplusonebio.com |
| Employees | 28 (19 on RocketReach) |
| Address | 313 Pleasant St 4W, Watertown, Massachusetts 02472, US |
| Industry | Biotechnology Research |
| Keywords | Rna Synthesis, Rna Technology, Rna Therapeutics, Rna Modification, Nucleic Acid Synthesis, Oligonucleotide Synthesis, Pharmaceutical Manufacturing, Biotechnology, Drug Discovery, Genetic Engineering, Molecular Biology, Rna Research, Life Sciences, Bioprocessing, Pharmaceutical Technology, Synthetic Biology, Gene Therapy |
| Competitors | Zymergen, Inc., Twist Bioscience, Codexis, Inc., Agilent Technologies, BASF, Amyris, Arzeda, Geno, Evolva, JUSTBIO +39 more (view full list) |
Looking for a particular EnPlusOne Biosciences employee's phone or email?
Clare Murray is the CEO of EnPlusOne Biosciences.
19 people are employed at EnPlusOne Biosciences.
EnPlusOne Biosciences is based in Watertown, Massachusetts.